Get started
Author

Benjamin Herzberg

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
2016 · Benjamin Herzberg, Meghan J. Campo, et al. · The Oncologist · 164
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
2026 · Brian M. Wolpin, Wungki Park, et al. · New England Journal of Medicine · 86
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
2024 · Xiuning Le, Jyoti D. Patel, et al. · Journal of Clinical Oncology · 55
Metastatic melanoma and immunotherapy
2016 · Benjamin Herzberg, David E. Fisher · Clinical Immunology · 53
Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis
2026 · Matthew G. Jones, Dawei Sun, et al. · Nature Genetics · 30
Epidermal RelA Specifically Restricts Contact Allergen–Induced Inflammation and Apoptosis in Skin
2014 · Snehlata Kumari, Benjamin Herzberg, et al. · Journal of Investigative Dermatology · 8
PDF
Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)
2026 · Eileen M. O'Reilly, Brian Wolpin, et al. · Cancer Research · 6
Severe scalp ulcerations and granulomata during treatment with amivantamab
2023 · Jingjia J Zhou, Lanyi N Chen, et al. · Current Problems in Cancer Case Reports · 4
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
2026 · Kathryn C. Arbour, Salman Punekar, et al. · New England Journal of Medicine · 3
Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights.
2026 · Wungki Park, Anup Kasi, et al. · Journal of Clinical Oncology · 2
PDF
A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.
2026 · Rahul Atul Parikh, Benjamin Herzberg, et al. · Journal of Clinical Oncology · 1
PDF
Current landscape of RAS-targeted therapy for pancreatic cancer
2026 · Y Linda Wu, Benjamin Herzberg, et al. · The Oncologist
PDF
IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted ( MTAP -Del) advanced solid tumors (IDE892001): Phase 1 trial.
2026 · Benjamin Garmezy, Benjamin Herzberg, et al. · Journal of Clinical Oncology
PDF
Works count: 13
Citation count: 412
H-index: 6
I10-index: 5
Year
Topic
Type